Fontana D J, Daniels S E, Wong E H, Clark R D, Eglen R M
Center for Biological Research, Roche Bioscience, Palo Alto, CA, USA.
Neuropharmacology. 1997 Apr-May;36(4-5):689-96. doi: 10.1016/s0028-3908(97)00055-5.
Activation of central 5-hydroxytryptamine (5-HT4) receptors may enhance cognitive performance. In the present study, the effects of two novel, potent and selective 5-HT4 receptor agonists, RS 67333 (1-(4-amino-5-chloro-2-methoxyphenyl)-3-(1-n-burtl-4-piperidinyl)- 1-propanone) and RS 67506 (1-(4-amino- 5-chloro-2-methoxyphenyl)-3-[1-[2-[(methylsulfonyl)amino]ethyl]-4- piperidinyl]-1-propanone), were studied in a rat model of spatial learning and memory; the Morris water maze. RS 67333 (0.1, 10 and 1000 micrograms/kg, intraperitoneally (i.p.)), a highly potent, selective and hydrophobic 5-HT4 receptor agonist, reversed the decrements in cognitive performance induced by atropine (30 mg/kg, i.p.). By contrast, no effect was seen to RS 67506 (0.1, 10 and 1000 micrograms/kg, i.p.), a hydrophilic 5-HT4 receptor agonist, of equivalent potency and selectivity to RS 67333. This differential effect may reflect the enhanced ability of RS 67333 to enter the CNS, with respect to RS 67506. The ameliorative actions of RS 67333 on cognitive dysfunction were abolished by prior treatment with a selective 5-HT4 receptor antagonist, RS 67532 [1-(4-amino-5-chloro-2-(3, 5-dimethoxy benzyloxyphenyl)-5-(1-piperidinyl)-1-pentanone; 1 mg/kg, i.p.]. When given alone, or in naive rats, RS 67532 (0.1, 10 and 1000 micrograms/kg, i.p.), was without effect. None of the compounds tested affected the swim speed at any of the doses used. In separate locomotor studies, RS 67532 reduced activity at 1 and 10 mg/kg, i.p., although no effect was seen with RS 67333 or RS 67506 (0.01-10 mg/kg, i.p.). These data suggest that RS 67333 reversed the cognitive deficit induced by atropine and support a role of 5-HT4 receptors in rat spatial learning and memory.
中枢5-羟色胺(5-HT4)受体的激活可能会提高认知能力。在本研究中,我们在大鼠空间学习和记忆模型——莫里斯水迷宫中,研究了两种新型、强效且选择性的5-HT4受体激动剂RS 67333(1-(4-氨基-5-氯-2-甲氧基苯基)-3-(1-正丁基-4-哌啶基)-1-丙酮)和RS 67506(1-(4-氨基-5-氯-2-甲氧基苯基)-3-[1-[2-[(甲磺酰基)氨基]乙基]-4-哌啶基]-1-丙酮)的作用。RS 67333是一种高效、选择性且疏水的5-HT4受体激动剂,腹腔注射(i.p.)剂量为0.1、10和1000微克/千克时,可逆转由阿托品(30毫克/千克,腹腔注射)引起的认知能力下降。相比之下,亲水性5-HT4受体激动剂RS 67506(腹腔注射剂量为0.1、10和1000微克/千克),其效力和选择性与RS 67333相当,却未产生任何效果。这种差异效应可能反映出相对于RS 67506,RS 67333进入中枢神经系统的能力更强。RS 67333对认知功能障碍的改善作用,在预先用选择性5-HT4受体拮抗剂RS 67532 [1-(4-氨基-5-氯-2-(3,5-二甲氧基苄氧基苯基)-5-(1-哌啶基)-1-戊酮;1毫克/千克,腹腔注射]处理后被消除。单独给药时,或在未处理的大鼠中,RS 67532(腹腔注射剂量为0.1、10和1000微克/千克)无作用。所测试的化合物在任何使用剂量下均未影响游泳速度。在单独的运动研究中,RS 67532在腹腔注射剂量为1和10毫克/千克时可降低活动能力,而RS 67333或RS 67506(腹腔注射剂量为0.01 - 10毫克/千克)则无此作用。这些数据表明,RS 67333可逆转由阿托品引起的认知缺陷,并支持5-HT4受体在大鼠空间学习和记忆中的作用。